Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines

Kaymakoglu, Sabahattin; TABAK, ÖMER FEHMİ

Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines

Sabahattin KAYMAKOĞLU, (Turkish Association for the Study of the Liver, Istanbul, Turkey Viral Hepatitis Society, Ankara, Turkey)

ÖMER FEHMİ TABAK (Turkish Association for the Study of the Liver, Istanbul, Turkey Viral Hepatitis Society, Ankara, Turkey)

Turkish Journal of Gastroenterology

3 0

Yıl: 2017 Cilt: 28 Sayı: 2 Sayfa Aralığı: 73 - 83 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines

Öz:

Dear Colleagues,Guidelines provide guidance to physicians in the diagnosis and management of diseases as well as to official authorities in the process of approval and reimbursement. The Turkish Association for the Study of the Liver (TASL) and Viral Hepatitis Society (VHS) have collaborated in the preparation of the first “Viral Hepatitis B, D and C: Diagnosis and Treatment Guideline” in 2015. Viral hepatitis are the most common risk factors posing a threat to liver health in our country while being one of the most dynamic topics in our scientific discipline. Therefore, there is definitely a need to update the guidelines based on the emerging information about diagnosis and treatment.In December 2016, the members of two societies organized for the update of “Turkish Viral Hepatitis Diagnosis and Treatment Guideline 2017” all viral hepatitis experts came together to cover the topics of diagnosis-patient evaluation-treatment-follow-up during and after treatment in instances of viral hepatitis B, C and D and to identify the principles of the guideline in unison. To this end, three different study groups were formed with joint participation of the members. Group I: Chronic Hepatitis B and D; Group II: Chronic Hepatitis C-Pretreatment evaluation (screening, diagnosis of acute-chronic hepatitis C, treatment indications, preparation for treatment), Follow-up of patients during and after treatment; Group III: Chronic Hepatitis C-Treatment. They first came to a consensus among themselves; they then finalized the principles of the guideline with the approval of all the participants.Under these principles, each group prepared a text that they had consensus on and presented this for the approval of all groups. The texts were finalized together with the feedback provided and the condition of 70% consensus was sought. Our guidelines in such an effort was the internationally accepted guidelines like European Association for the Study of Liver (EASL), American Association for the Study of Liver Disease (AASLD) and Asian Pacific Association for the Study of Liver (APASL). Drugs approved by Food and Drug Administration (FDA), European Medicines Agency (EMA), Japan, Canada and Australia were recommended as treatment regimens. This guideline is supported by the memberships of the TASL and VHS and not by pharmaceutical companies. We hope that “Turkey Viral Hepatitis Diagnosis and Treatment Guideline 2017” will be a useful tool for all of us

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39. [CrossRef]
2. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1-33.
3. Lindh M, Uhnoo I, Blackberg J, et al. Treatment of chronic hepatitis B infection: an update of Swedish recommendations. Scand J Infect Dis 2008; 40: 436-50. [CrossRef]
4. Curry MP, Chopra S. Acute Viral Hepatitis. Mandell GL, Bennett JE, Dolin R, editors. Principlesand Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2005.p.1426-41.
5. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351-66.
6. Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J Hepatol 1997; 26: 62-8. [CrossRef]
7. Bismuth H, Samuel D, Castaing D, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg 1995; 222: 109-19. [CrossRef]
8. Emond JC, Aran PP, Whitington PF, Broelsch CE, Baker AL. Liver transplantation in the management of fulminant hepatic failure. Gastroenterology 1989; 96: 1583-88. [CrossRef]
9. McMahon BJ. Selecting appropriate management strategies for chronic hepatitis B: who to treat. Am J Gastroenterol 2006; 101 Suppl1: S7-12. [CrossRef]
10. Sharma SK, Saini N, Chwla Y. Hepatitis B Virus: Inactive carriers. Virol J 2005; 2: 82. [CrossRef]
11. Lok A. DDW PG Course 2013; Anna Lok, Esteban R. Overview of the management of hepatitis B. Uptodate November 2014.
12. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150: 104-10. [CrossRef]
13. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-98. [CrossRef]
14. Castera L, Bernard PH, Le BB et al. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther 2011; 33: 455-65. [CrossRef]
15. Cardoso AC, Carvalho-Filho RJ, Marcellin P. Transient elastography in chronic viral hepatitis: a critical appraisal. Gut 2011; 60: 759-64. [CrossRef]
16. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-9. [CrossRef]
17. Rijckborst V, Hansen BE, Ferenci P et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-11. [CrossRef]
18. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-42. [CrossRef]
19. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus ınfection in the United States: 2008 Update. Clin Gastroenterol Hepatol 2008; 6: 1315-41. [CrossRef]
20. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. 2009; 50: 661-2.
21. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009. [CrossRef]
22. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAgpositive chronic hepatitis B: a randomized trial. Lancet 2005; 365: 123. Türkiye Viral Hepatitler Tanı ve Tedavi Kılavuzu 2017: 37.
23. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-91. [CrossRef]
24. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31. [CrossRef]
25. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre and post-liver transplantation patients. Hepatology 2003; 38: 1419-27. [CrossRef]
26. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10. [CrossRef]
27. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679-93.
28. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65. [CrossRef]
29. Fung SK, Fontana RJ. Management of drug-resistant chronic hepatitis B. Clin Liver Dis 2006; 10: 275-302. [CrossRef]
30. Fung SK, Lok AS. Management of hepatitis B patients with antiviral resistance. Antivir Ther 2004; 9: 1013-26.
31. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-9. [CrossRef]
32. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovirresistant mutations. J Hepatol 2008; 48: 391-8.[CrossRef]
33. Goulis I, Dalekos GN. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. Expert Rev Anti Infect Ther 2008; 6: 855-9. [CrossRef]
34. Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis 2007; 11: 869-92. [CrossRef]
35. Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008; 6: 268-74. [CrossRef]
36. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95. [CrossRef]
37. Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B: A multicenter and randomized trial (ARES study). Hepatology 2015; 61: 1512-22. [CrossRef]
38. Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a ıncreases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016; 150: 134-44. [CrossRef]
39. Metcalf M, Brown N, Peterson S, et al. Health care costs associated with chronic hepatitis B. Am J Health Syst Pharm 1999; 56: 232-6.
40. Sun X, Qin WX, Li YP, Jiang XH. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. J Gastroenterol Hepatol 2007; 22: 1369-77. [CrossRef]
41. Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol 2001; 16: 301-8. [CrossRef]
42. Lapinski TW, Flisiak R, Jaroszewicz J, Michalewicz M, Kowalczuk O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol 2005; 11: 400-2. [CrossRef]
43. Fontaine H, Vallet-Pichard A, Chaix ML, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with adrenalin sufficiency. Transplantation 2005; 80: 1086-92. [CrossRef]
44. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427-37. [CrossRef]
45. Fehr T, Ambühl PM. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19: 1049-53. [CrossRef]
46. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77: 859-64. [CrossRef]
47. Tan J, Lok AS. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 2007; 13: 323-6. [CrossRef]
48. Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19: 6-12. [CrossRef]
49. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for waitlisted and post-liver transplantation patients with lamivudineresistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-60. [CrossRef]
50. Karasu Z, Ozacar T, Akyildiz M, et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004; 9: 921-7.
51. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-7. [CrossRef]
52. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-9. [CrossRef]
53. Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-81. [CrossRef]
54. Gish RG, Keeffe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J Hepatol 1995; 22: 257-62. [CrossRef]
55. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122: 264-73. [CrossRef]
56. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemolipiodolization. Hepatology 2006; 43: 233-40. [CrossRef]
57. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597-603. [CrossRef]
58. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006; 24: 1003-16. [CrossRef]
59. Van Zonneveld M, Van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-7. [CrossRef]
60. Rapti IN, Hadziyannis SJ. Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol Hepatol 2011; 5: 323-37. [CrossRef]
61. Lee, NM, Brady CW. Liver disease in pregnancy. World J Gastroenterol 2009; 15: 897- 906. [CrossRef]
62. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2: 1099-102. [CrossRef]
63. Benaboud S, Pruvost A, Coffie PA, et al. Concentrations of tenofovir and emtricitabine in breastmilk of HIV-1- infected women in Abidjan, Coted'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011; 55: 1315-7. [CrossRef]
64. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85. [CrossRef]
65. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-83. [CrossRef]
66. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001; 10: 751-74. [CrossRef]
67. Beutels P, Edmunds WJ, Antonanzas F, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20: 1-7. [CrossRef]
68. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-9. [CrossRef]

APA	Kaymakoglu S, TABAK Ö (2017). Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. , 73 - 83.
Chicago	Kaymakoglu Sabahattin,TABAK ÖMER FEHMİ Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. (2017): 73 - 83.
MLA	Kaymakoglu Sabahattin,TABAK ÖMER FEHMİ Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. , 2017, ss.73 - 83.
AMA	Kaymakoglu S,TABAK Ö Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. . 2017; 73 - 83.
Vancouver	Kaymakoglu S,TABAK Ö Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. . 2017; 73 - 83.
IEEE	Kaymakoglu S,TABAK Ö "Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines." , ss.73 - 83, 2017.
ISNAD	Kaymakoglu, Sabahattin - TABAK, ÖMER FEHMİ. "Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines". (2017), 73-83.

APA	Kaymakoglu S, TABAK Ö (2017). Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. Turkish Journal of Gastroenterology, 28(2), 73 - 83.
Chicago	Kaymakoglu Sabahattin,TABAK ÖMER FEHMİ Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. Turkish Journal of Gastroenterology 28, no.2 (2017): 73 - 83.
MLA	Kaymakoglu Sabahattin,TABAK ÖMER FEHMİ Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. Turkish Journal of Gastroenterology, vol.28, no.2, 2017, ss.73 - 83.
AMA	Kaymakoglu S,TABAK Ö Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. Turkish Journal of Gastroenterology. 2017; 28(2): 73 - 83.
Vancouver	Kaymakoglu S,TABAK Ö Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. Turkish Journal of Gastroenterology. 2017; 28(2): 73 - 83.
IEEE	Kaymakoglu S,TABAK Ö "Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines." Turkish Journal of Gastroenterology, 28, ss.73 - 83, 2017.
ISNAD	Kaymakoglu, Sabahattin - TABAK, ÖMER FEHMİ. "Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines". Turkish Journal of Gastroenterology 28/2 (2017), 73-83.